Fraud on FDA pedicle screws lawsuit thrown out
This article was originally published in Clinica
In a landmark case, fraud on the US FDA is not a valid ground for collecting damages in product liability cases filed in a state court, the US Supreme Court ruled last week.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.